MS: Busting the Myths
August 21, 2017
New Special Authority criteria From 1 July 2022, funded access to the eight funded MS treatments will be amended in Section B (the Community) of the Pharmaceutical Schedule. Equivalent changes will also be made in Part II of Section H […]